Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured other health measures

12-week NMN trial in 60 older adults: no clear gain on main stepping test

Morifuji and colleagues · GeroScience · 2024

Original title: Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No difference

The main test (stepping test) showed no difference at 4 or 12 weeks. At 12 weeks the NMN group had a shorter 4-m walking time and better sleep scores than placebo.

The study at a glance

Type of study
Randomized trial
Who or what was studied
60 people · Older adults
What was tested
NMN 250 mg a day for 12 weeks, vs placebo
What it measured
Other health or performance measures
Daily amount
250 mg a day
How long
12 weeks
Trial registration
UMIN000047871
Who has a stake
Company stake
Three authors are employees of Meiji Holding Co., Ltd.
Journal
GeroScience, 2024
Source
PubMed record 38789831. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •Medium size: 60 people.
  • •Lasted 12 weeks.
  • •Measured other health measures, not aging and age-related decline itself.
  • –Company stake: Three authors are employees of Meiji Holding Co., Ltd.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 8 papers on the same step: 3 benefit, 2 mixed, 3 no difference. This one found no difference.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 1 field after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.